Vision Meets Innovation: Leading in Life Sciences with David Esposito
In this episode, we interview David Esposito, an experienced healthcare CEO with a background in both large pharma and early-stage biotech. David discusses his career journey, insights into leading and scaling healthcare companies, and the challenges and opportunities in developing innovative therapies for diseases of the eye. He also shares his perspective on leadership, team building, and the importance of maintaining a focus on patient outcomes.
Chapters/Timestamps:
Chapters/Timestamps:
- 00:00 - Introduction and David Esposito's Background
- 02:09 - ONL Therapeutics and its Focus
- 09:05 - David Esposito’s Career Journey
- 24:47 - Leadership and Team Building
- 32:35 - Challenges in Biotech and Company Growth
- 48:22 - Marketing and Clinical Trial Enrollment
- 58:52 - Funding and Future Outlook
- 1:09:09 - Inspiration and Advice
- 1:19:31 - The Future of Healthcare Innovation
Guest Information:
- Guest's Name: David Esposito
- Guest's Title/Position: CEO
- Company/Affiliation: ONL Therapeutics
- Guest's Bio: David Esposito is an experienced healthcare CEO with over thirty years in the industry. He has a background in large pharma and has built and scaled multiple early to mid-stage life science companies. Currently, he is the CEO of ONL Therapeutics, a mid-stage biotech company focused on developing therapies for diseases of the eye.
Links and Resources:
- ONL Therapeutics: https://onltherapeutics.com/
- RA Capital: https://www.racap.com/
- Andreessen Horowitz: https://a16z.com/
Creators and Guests
Host
Heath Fletcher
With over 30 years in creative marketing and visual storytelling, I’ve built a career on turning ideas into impact. From brand transformation to media production, podcast development, and outreach strategies, I craft compelling narratives that don’t just capture attention—they accelerate growth and drive measurable results.
Guest
David Esposito
David Esposito is an experienced health care executive who has built and scaled multiple companies, resulting in successful exits to strategic buyers. He is the former CEO of Armune BioScience, where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017. David was president of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. He began his career as a sales representative with Merck & Co. Inc., rising through the ranks of sales, marketing and commercial strategy for the U.S. division. As a combat veteran, David led an infantry platoon with the 101st Airborne Division through several combat operations and was recognized with a Bronze Star for combat action in Iraq in 1991. He earned his bachelor’s degree in civil engineering from the U.S. Military Academy at West Point and his MBA from Syracuse University.